Xbiotech Inc (XBIT)

$2.55 -0.02 (-0.78%)
Market Cap 78.35M
Revenue (ttm) 0.00
Net Income (ttm) -45.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,800
Avg Vol 35,340
Day's Range N/A - N/A
Shares Out 30.49M
Stochastic %K 58%
Beta 0.84
Analysts Strong Buy
Price Target $18.00

Company Profile

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 386 2900
Fax: 512 386 5505
Address:
5217 Winnebago Lane, Austin, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 13 at 12:29 PM
$XBIT RSI: 41.43, MACD: -0.0080 Vol: 0.04, MA20: 2.32, MA50: 2.35 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 8:46 PM
$XBIT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 7:15 PM
$XBIT RSI: 38.64, MACD: -0.0442 Vol: 0.13, MA20: 2.45, MA50: 2.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TapeBenji
TapeBenji Feb. 20 at 4:36 PM
$XBIT Crypto-linked ETF driven by digital asset sentiment. Volatility is extreme. Fundamentals are secondary to flows.
0 · Reply
HexBlade
HexBlade Feb. 17 at 8:59 AM
$XBIT Pre-revenue biotech; early-stage
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 11:46 AM
$XBIT RSI: 34.85, MACD: -0.0041 Vol: 0.09, MA20: 2.57, MA50: 2.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 2:13 PM
$XBIT Great piece that accurately captures XBIT's current position. So if you want to refresh your understanding of XBIT or learn about XBIT for the first time, this is essential reading. https://everyticker.com/quote/XBIT/analysis/xbiotech-unlocking-natural-immunity-and-manufacturing-innovation-for-future-growth-nasdaq-xbit
0 · Reply
Trekingirl
Trekingirl Jan. 29 at 11:42 AM
$XBIT I like to see this one go up, but Schwab says volume 1 share. Can't be right. Could it?
0 · Reply
ImpossibilityI
ImpossibilityI Dec. 27 at 5:34 AM
$XBIT Markets appear to be rewarding companies that show durable execution rather than rapid narrative shifts. Operational cadence needs to tighten meaningfully. If milestones become dependable, sentiment could re‑rate quickly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 4:55 PM
$XBIT Share Price: $2.48 Contract Selected: Apr 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 60% ROI Time to Expiration: 111 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on XBIT
The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 29, 2025, 10:00 AM EST - 1 year ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation

Jan 28, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud

Jan 27, 2025, 11:15 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect

Jan 27, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out

Jan 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 23, 2025, 10:00 AM EST - 1 year ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect

Jan 22, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation

Jan 21, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation

Jan 19, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation

Jan 17, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Jan 17, 2025, 5:19 AM EST - 1 year ago

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out

Jan 16, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud

Jan 15, 2025, 11:15 AM EST - 1 year ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Jan 14, 2025, 4:37 PM EST - 1 year ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

Jan 14, 2025, 11:15 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.

Jan 13, 2025, 9:15 PM EST - 1 year ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.

XBiotech Pauses Rheumatology program

Dec 23, 2024, 9:00 AM EST - 1 year ago

XBiotech Pauses Rheumatology program

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Jun 18, 2024, 1:08 PM EDT - 2 years ago

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Jun 18, 2024, 11:35 AM EDT - 2 years ago

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Jan 4, 2024, 9:00 AM EST - 2 years ago

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

Nov 14, 2023, 9:00 AM EST - 2 years ago

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Sep 26, 2023, 9:00 AM EDT - 2 years ago

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

Aug 30, 2023, 9:00 AM EDT - 2 years ago

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

Aug 8, 2023, 11:47 AM EDT - 2 years ago

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 22, 2023, 9:00 AM EDT - 3 years ago

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 13 at 12:29 PM
$XBIT RSI: 41.43, MACD: -0.0080 Vol: 0.04, MA20: 2.32, MA50: 2.35 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 8:46 PM
$XBIT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 7:15 PM
$XBIT RSI: 38.64, MACD: -0.0442 Vol: 0.13, MA20: 2.45, MA50: 2.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TapeBenji
TapeBenji Feb. 20 at 4:36 PM
$XBIT Crypto-linked ETF driven by digital asset sentiment. Volatility is extreme. Fundamentals are secondary to flows.
0 · Reply
HexBlade
HexBlade Feb. 17 at 8:59 AM
$XBIT Pre-revenue biotech; early-stage
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 11:46 AM
$XBIT RSI: 34.85, MACD: -0.0041 Vol: 0.09, MA20: 2.57, MA50: 2.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 2:13 PM
$XBIT Great piece that accurately captures XBIT's current position. So if you want to refresh your understanding of XBIT or learn about XBIT for the first time, this is essential reading. https://everyticker.com/quote/XBIT/analysis/xbiotech-unlocking-natural-immunity-and-manufacturing-innovation-for-future-growth-nasdaq-xbit
0 · Reply
Trekingirl
Trekingirl Jan. 29 at 11:42 AM
$XBIT I like to see this one go up, but Schwab says volume 1 share. Can't be right. Could it?
0 · Reply
ImpossibilityI
ImpossibilityI Dec. 27 at 5:34 AM
$XBIT Markets appear to be rewarding companies that show durable execution rather than rapid narrative shifts. Operational cadence needs to tighten meaningfully. If milestones become dependable, sentiment could re‑rate quickly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 4:55 PM
$XBIT Share Price: $2.48 Contract Selected: Apr 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 60% ROI Time to Expiration: 111 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Notknowing
Notknowing Dec. 17 at 3:24 PM
$XBIT what's the purpose of this company? management self enrichment until zero cash? or ist there still a better agenda for investors, since some specific guys have substaintial share holidngs?
0 · Reply
theBigDollarski
theBigDollarski Dec. 12 at 9:58 PM
$XBIT simard gets 11MM golden parachute plus retains seat on board....all this with nothing in their pipeline...pure thievery
1 · Reply
MarkZH
MarkZH Dec. 9 at 6:46 PM
$XBIT Maybe new CEO will be more informative?!?
0 · Reply
DARKP00L
DARKP00L Dec. 9 at 2:38 PM
$XBIT 09:13 on Dec. 09 2025 XBiotech Announces John Simard To Retire As CEO, To Continue As Chairman; Sushma Shivaswamy Appointed Interim CEO #tradeideas
0 · Reply
MarkZH
MarkZH Dec. 9 at 2:22 PM
$XBIT CEO stepping down
0 · Reply
theBigDollarski
theBigDollarski Nov. 19 at 9:15 PM
$XBIT wtf??
0 · Reply
theBigDollarski
theBigDollarski Nov. 12 at 6:03 PM
$XBIT this is a shell company..John Simard's piggy bank
0 · Reply
baj10se
baj10se Nov. 12 at 5:24 PM
$XBIT 5 filings out today - Form 4's and the 10-Q . They have 153M cash on hand...$4.83 per share
0 · Reply
Lalalilala
Lalalilala Nov. 12 at 1:09 PM
$XBIT Place a buy order at $2.50 to initiate a position pending new data.
1 · Reply
Lalalilala
Lalalilala Nov. 12 at 1:01 PM
$XBIT Ok , 2,50$ / 2$ today. Yesterday = P&D Down.
0 · Reply
Lalalilala
Lalalilala Nov. 12 at 11:01 AM
$XBIT 16:00 =>> 2,50 or 3,50$ ? 🤔
0 · Reply
SadyK189
SadyK189 Nov. 12 at 2:29 AM
Top Stocks to watch tomorrow 2 / 2: $RIVN $LUCY $IRWD $ZURA $XBIT RIVN: Looking good on daily chart. 16.10 - 16.60 is acting as key support zone. Next key level to test is 19.60 - 20.10. Overall it has long term potential of 24+ ZURA: Good close of daily candle. Key support at 3.4 - 3.8. Next key level to test is 4.95 - 5.30. Currently at 4.41. IRWD is trending nicely on daily chart. 2.15 - 2.35 is acting as key support zone. Next key level to test is 3.35 - 3.55. Currently at 2.95 LUCY: Good close of 4hours candle. Key support at 1.55 - 1.70. Next key level to test is 2.6 - 2.9. Currently at 2.17 XBIT tried to clear stiff resistance of 3.3 - 3.6 zone today but got rejected. Currently at 2.83. It may test this zone again.
0 · Reply